The pathologist's view point. Part I - Indolent lymphomas

S. A. Pileri, S. Ascani, E. Sabattini, G. Fraternali-Orcioni, S. Poggi, M. Piccioli, P. P. Piccaluga, B. Gamberi, P. L. Zinzani, L. Leoncini, B. Falini

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background and Objectives. The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. Data Sources and Methods. Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. Results. Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. Interpreation and Conclusions. The present knowledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.

Original languageEnglish
Pages (from-to)1291-1307
Number of pages17
JournalHaematologica
Volume85
Issue number12
Publication statusPublished - 2000

Fingerprint

Lymphoma
Information Storage and Retrieval
B-Cell Lymphoma
Organizations
Guidelines
Therapeutics
Pathologists
Neoplasms

Keywords

  • Behavior
  • Genotype
  • Indolent lymphoma
  • Morphology
  • Phenotype

ASJC Scopus subject areas

  • Hematology

Cite this

Pileri, S. A., Ascani, S., Sabattini, E., Fraternali-Orcioni, G., Poggi, S., Piccioli, M., ... Falini, B. (2000). The pathologist's view point. Part I - Indolent lymphomas. Haematologica, 85(12), 1291-1307.

The pathologist's view point. Part I - Indolent lymphomas. / Pileri, S. A.; Ascani, S.; Sabattini, E.; Fraternali-Orcioni, G.; Poggi, S.; Piccioli, M.; Piccaluga, P. P.; Gamberi, B.; Zinzani, P. L.; Leoncini, L.; Falini, B.

In: Haematologica, Vol. 85, No. 12, 2000, p. 1291-1307.

Research output: Contribution to journalArticle

Pileri, SA, Ascani, S, Sabattini, E, Fraternali-Orcioni, G, Poggi, S, Piccioli, M, Piccaluga, PP, Gamberi, B, Zinzani, PL, Leoncini, L & Falini, B 2000, 'The pathologist's view point. Part I - Indolent lymphomas', Haematologica, vol. 85, no. 12, pp. 1291-1307.
Pileri SA, Ascani S, Sabattini E, Fraternali-Orcioni G, Poggi S, Piccioli M et al. The pathologist's view point. Part I - Indolent lymphomas. Haematologica. 2000;85(12):1291-1307.
Pileri, S. A. ; Ascani, S. ; Sabattini, E. ; Fraternali-Orcioni, G. ; Poggi, S. ; Piccioli, M. ; Piccaluga, P. P. ; Gamberi, B. ; Zinzani, P. L. ; Leoncini, L. ; Falini, B. / The pathologist's view point. Part I - Indolent lymphomas. In: Haematologica. 2000 ; Vol. 85, No. 12. pp. 1291-1307.
@article{5cabf9d895224fe39c83f92b57b8e552,
title = "The pathologist's view point. Part I - Indolent lymphomas",
abstract = "Background and Objectives. The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. Data Sources and Methods. Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. Results. Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. Interpreation and Conclusions. The present knowledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.",
keywords = "Behavior, Genotype, Indolent lymphoma, Morphology, Phenotype",
author = "Pileri, {S. A.} and S. Ascani and E. Sabattini and G. Fraternali-Orcioni and S. Poggi and M. Piccioli and Piccaluga, {P. P.} and B. Gamberi and Zinzani, {P. L.} and L. Leoncini and B. Falini",
year = "2000",
language = "English",
volume = "85",
pages = "1291--1307",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - The pathologist's view point. Part I - Indolent lymphomas

AU - Pileri, S. A.

AU - Ascani, S.

AU - Sabattini, E.

AU - Fraternali-Orcioni, G.

AU - Poggi, S.

AU - Piccioli, M.

AU - Piccaluga, P. P.

AU - Gamberi, B.

AU - Zinzani, P. L.

AU - Leoncini, L.

AU - Falini, B.

PY - 2000

Y1 - 2000

N2 - Background and Objectives. The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. Data Sources and Methods. Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. Results. Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. Interpreation and Conclusions. The present knowledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.

AB - Background and Objectives. The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. Data Sources and Methods. Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. Results. Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. Interpreation and Conclusions. The present knowledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.

KW - Behavior

KW - Genotype

KW - Indolent lymphoma

KW - Morphology

KW - Phenotype

UR - http://www.scopus.com/inward/record.url?scp=0034515209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034515209&partnerID=8YFLogxK

M3 - Article

C2 - 11114137

AN - SCOPUS:0034515209

VL - 85

SP - 1291

EP - 1307

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -